Latka logo
Immunome logo

Immunomerevenue & market cap

Bothell, WashingtonFounded 2006

Public company

Immunome is a clinical-stage biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, focusing on improving outcomes for cancer patients.

immunome.comLinkedInUpdated Sep 29, 2026
Annual revenue
$6.9M
Dec 2025 · Stock Analysis−23% YoY
Market cap
$2.5B
Sep 2026

Immunome revenue

Immunome's annual revenue was $6.9M in December 2025 (Stock Analysis). That is down 23% from $9M a year earlier.

$0
$2.5M
$5M
$7.5M
$0
–
$9M
$6.9M
20062007–2320242025
ReportedFounded 2006 at $0; every reading has its own bar
All 2 revenue readings, with sources
As ofRevenueSource
Dec 2024$9MStock Analysis
Dec 2025$6.9MStock Analysis

Immunome market cap

Immunome is a public company. Its market capitalisation was $2.5B in September 2026.

Immunome FAQ

What is Immunome's revenue?

Immunome's annual revenue was $6.9M in December 2025, according to Stock Analysis.

Is Immunome publicly traded?

Yes. Immunome is a public company, with a market capitalisation of $2.5B in September 2026.

Categories

How this page is sourced

2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 29, 2026Data disclaimerReport a correctionClaim this profileRun Immunome? Join the podcast